CN1305477C - Paint for treating benign prostate hyperplasia and its use - Google Patents
Paint for treating benign prostate hyperplasia and its use Download PDFInfo
- Publication number
- CN1305477C CN1305477C CNB2003101184767A CN200310118476A CN1305477C CN 1305477 C CN1305477 C CN 1305477C CN B2003101184767 A CNB2003101184767 A CN B2003101184767A CN 200310118476 A CN200310118476 A CN 200310118476A CN 1305477 C CN1305477 C CN 1305477C
- Authority
- CN
- China
- Prior art keywords
- liniment
- category
- chemical compound
- bph
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 43
- 239000003973 paint Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 58
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims abstract description 38
- 229940040145 liniment Drugs 0.000 claims description 30
- 239000000865 liniment Substances 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 210000002307 prostate Anatomy 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 5
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000011248 coating agent Substances 0.000 abstract 4
- 239000000470 constituent Substances 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 230000002390 hyperplastic effect Effects 0.000 abstract 1
- 239000002085 irritant Substances 0.000 abstract 1
- 231100000021 irritant Toxicity 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 27
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 18
- 210000002700 urine Anatomy 0.000 description 12
- 206010029446 nocturia Diseases 0.000 description 11
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 10
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 9
- 241000772415 Neovison vison Species 0.000 description 9
- 229920001214 Polysorbate 60 Polymers 0.000 description 9
- 229920002674 hyaluronan Polymers 0.000 description 9
- 229960003160 hyaluronic acid Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010046543 Urinary incontinence Diseases 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 206010013990 dysuria Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000037157 Azotemia Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940031955 anhydrous lanolin Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002885 octadecanoids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000024449 overflow incontinence Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000004908 prostatic fluid Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000003202 urodynamic effect Effects 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a coating agent for treating benign prostatic hyperplasia (BPH) and an application thereof. The coating agent of the present invention contains at least one or some of active constituent compounds, has the advantages of conspicuous curative effect, no side effect, persistent effect and easy use, and can be coated on the skin. The coating agent can effectively get rid of irritant symptoms caused by BPH and can reduce the volume of the hyperplastic prostate if used continuously; the coating agent can treat both manifestations and root cause of diseases.
Description
Technical field
The present invention relates to a kind of Liniment and uses thereof, more particularly relate to Liniment for the treatment of benign prostatic hyperplasia (BPH) and uses thereof.
Background technology
Prostatic hyperplasia or benign prostatic hyperplasia (BPH) claim prostate optimum hypertrophy again, are a kind of special organization pathological conditions, and its feature shows as substrate and epithelial hypertrophy.BPH can cause the increase (BPE) of benign prostate and the displayable benign prostate of urodynamics to block (BPO).BPH is not single disease, but the combination of the many symptoms that produce by many causes of disease.This disease has three principal characters: prostate volume increases; Bladder outlet blocks; Lower urinary tract symptoms such as dysuria, frequent micturition, urgent micturition are arranged.
Except these principal characters, hyperplasia of prostate can also cause a series of complication: the one, and may damage kidney even cause uremia.This is because outgrowth prostate is oppressed urethra, and bladder need firmly shrink, and just can overcome resistance urine is excreted, and in the course of time, it is plump that bladder muscle can become.If the pressure of bladder can not be removed for a long time, remaining in intravesical urine progressively increases, and bladder muscle will hypoxic-ischemic, become and do not have tension force, bladder cavity enlarges, and the urine in the last bladder can be poured in down a chimney to ureter, renal pelvis and be caused hydronephrosis, occurs uremia when serious.The secondth, cause vesical calculus.Under the unobstructed situation of urinary tract, generally can not grow stone in the bladder, also can discharge even there is stone to drop in the bladder with urine from ureter.The old people who suffers from prostatic hyperplasia is then different.The 3rd, hyperplasia of prostate can bring out old people's hernia diseases such as (small intestine-QIs).The dysuria symptom can appear in the hyperplasia of prostate patient who has, need firmly and feel suffocated and just can urinate, because often firmly, what intestines will be from the abdominal part weakness is local outstanding, form hernia (small intestine-QI), the patient also hemorrhoid, varicose veins of the lower extremity can occur sometimes.The 4th, easily cause infection.As the saying goes: " Running water never becomes putrid ", but the hyperplasia of prostate patient often has urine retention situation in various degree, and intravesical remaining urine just looks like a pool of stagnant water, in case bacterial reproduction will cause unmanageable infection.The 5th, cause urine retention and urinary incontinence.Urine retention can occur in any stage of disease, many because climate change, drink, fatigue makes that prostate is congested suddenly, edema institute extremely, too much residual urine can make bladder lose contractility, being trapped in intravesical urine increases gradually, when bladder excessive expands, urine can be overflowed from urethral orifice unconsciously, and the phenomenon of this urine incontinence is called urinary retention with overflow incontinence, and such patient must accept emergency treatment.
Prostatic hyperplasia is the male senile patient common frdquently encountered disease, sends out a patient among 50 years old crowd and accounts among 40%, 80 years old crowd closely 90%, during to 90 years old, then almost 100% suffers from prostatic hyperplasia.
Since oneth century, operation is as the method for unique treatment BPH, and the incidence rate of operation and complication is higher once more, and it is impaired also can sexual function to occur sometimes after the operation; Because benign prostatauxe disease patient mostly is the old people greatly, performing an operation also has certain danger; And studies show that in recent years; prostate participates in the composition of seminal fluid except that the secretion prostatic fluid; can also produce the panimmunity globulin, synthetic have an antibacterial action contain the zinc polypeptide, the protection reproductive system exempts from the local immunity function of antibacterial and the invasion and attack of other pathogenic microorganisms.Therefore, medical circle advocates that generally Drug therapy should be as first-line Therapeutic Method, should avoid operation as far as possible, and prostate is kept.
Be used for the treatment of at present BPH medicine quantity seldom, and medicine all has side effect in various degree, how using the modern biology theory, develop the medicine or the dosage form of (or nothing) evident in efficacy, low side effect, efficacy stability, is the target that present medical circle is pursued.
Summary of the invention
The purpose of this invention is to provide a kind of curative effect and be better than present medicine, have no side effect, prepare Liniment of easy treatment benign prostatic hyperplasia (BPH) and uses thereof substantially.
Technical solution of the present invention is as follows:
The Liniment of treatment benign prostatic hyperplasia (BPH) contains any chemical compound of selecting respectively from following A and B two compounds;
Its consumption is counted by weight: category-A 0.1-30, category-B 0.1-50;
The category-A chemical compound is to have structural formula to be (I), (II), (III) compound or its salt (IV):
Wherein R shows the arbitrary group in the following group of generation:
The category-B chemical compound is for having the following compound or its salt of structural formula for (V), (VI), (VII), (VIII):
Preferred version of the present invention is to contain wantonly two kinds of chemical compounds of selecting in any and the category-B chemical compound of selecting from the category-A chemical compound respectively in the Liniment.
Another preferred version of the present invention is to contain any chemical compound of selecting in wantonly two kinds and the category-B chemical compound of selecting from the category-A chemical compound in the Liniment.
Another preferred version of the present invention is to contain any two chemical compounds of selecting in any two and the category-B chemical compound of selecting from the category-A chemical compound in the Liniment.
Another preferred version of the present invention is that the Liniment consumption is counted by weight: category-A 5-25, category-B 5-30.
Another preferred version of the present invention is that the Liniment consumption is counted by weight: category-A 10-20, category-B 10-20.
The present invention also provides described Liniment to be used for the treatment of the purposes of benign prostatic hyperplasia.
Liniment provided by the invention can be made cream/frost/Emulsion, is coated on the human body skin.
Liniment of the present invention can contain in the cosmetics auxiliary agent and water commonly used: animal and plant fat (as Oleum Ricini), wetting agent (as commercially available commodity H.A by name), antibiotic antiseptic (as commodity Kathon CG by name), surfactant (as tween 80), spice (as jasmine fragrance) and antioxidant (are decided according to the resting period, if deposit more than 2 years, add some antioxidant, as BHA), synthesizing water-solubility macromolecular compound (as Polyethylene Glycol PEG) etc.
Liniment provided by the invention has following advantage: evident in efficacy, can reach or be better than the curative effect of present various treatment BPH medicines, and long-acting and safe and reliable; Have no side effect or extremely slight side effect, but life-time service; Preparation and easy to use, smear every day once, but smeared once in part patient 2-3 days, can effectively remove the irritative symptoms that causes by BPH (as frequent micturition, nocturia increase, urgent micturition, dysurea etc.) and block symptom (as dysuria, urinate hesitate, urinate that line attenuates, intermittence is urinated, last dribbling, urine retention sense etc. eventually) and urine pool slide, urinary incontinence, life-time service can make the body of prostate of increase dwindle, and the effect for the treatment of both the principal and secondary aspects of a disease is arranged.
The specific embodiment
Make the cream of Liniment of the present invention with conventional method, be coated on the human body skin.
Usage: spread upon skin surface as smearing vanishing cream, smear once and get final product every day.
Embodiment 1
Hexadecanol 5
Lanoline 4
Lanonol 4
White oil 5
Mink oil 2
1-positive dodecyl aza cyclohepta-2-ketone 5
Glycerol tristearate 5
Si Ben-60 4
Tween-60 2
Glycerol 5
Hyaluronic acid 0.5
Triumphant loose CG 0.05
Chemical compound 2 0.1
Chemical compound 9 0.1
Surplus is H
2O complements to 100.
Observation of curative effect on probation:
Urinating, to block the improvement rate be 91%, and it is 67% that the nocturia number of times improves effective percentage, and AFR is increased to (6.5 ± 2.2) ml/s by (4.6 ± 2) ml/s before treating after the treatment.
Embodiment 2
Chemical compound 6 30
Chemical compound 12 50
Octadecanoid acid 2
Hexadecanol 1
Anhydrous lanolin 1
White oil 1
1-positive dodecyl aza cyclohepta-2-ketone 3
Myristic acid isopropyl ester 2
Si Ben-60 1
Triethanolamine 1
Propylene glycol 2
Triumphant loose CG 0.05
Surplus is H
2O complements to 100.
Observation of curative effect on probation:
Urinating, to block the improvement rate be 98%, and it is 97% that the nocturia number of times improves effective percentage, and AFR is increased to (7.8 ± 2.7) ml/s by (4.1 ± 2.1) ml/s before treating after the treatment.
Embodiment 3
Hexadecanol 3
Lanoline 2
Lanonol 2
White oil 3
Mink oil 1
1-positive dodecyl aza cyclohepta-2-ketone 3
Glycerol tristearate 3
Si Ben-60 2
Tween-60 1
Glycerol 3
Hyaluronic acid 0.5
Triumphant loose CG 0.05
Chemical compound 3 0.1
Chemical compound 11 15
Chemical compound 12 35
Surplus is H
2O complements to 100.
Observation of curative effect on probation:
Urinating, to block the improvement rate be 92%, and it is 68% that the nocturia number of times improves effective percentage, and AFR is increased to (6.7 ± 2.2) ml/s by (4.5 ± 2) ml/s before treating after the treatment.
Embodiment 4
Hexadecanol 5
Lanoline 4
Lanonol 4
White oil 5
Mink oil 2
1-positive dodecyl aza cyclohepta-2-ketone 5
Glycerol tristearate 5
Si Ben-60 4
Tween-60 2
Glycerol 5
Hyaluronic acid 0.5
Triumphant loose CG 0.05
Chemical compound 8 15
Chemical compound 5 15
Chemical compound 11 0.1
Surplus is H
2O complements to 100.
Observation of curative effect on probation:
Urinating, to block the improvement rate be 94%, and it is 78% that the nocturia number of times improves effective percentage, and AFR is increased to (7.5 ± 2.2) ml/s by (4.2 ± 2) ml/s before treating after the treatment.
Embodiment 5
Hexadecanol 5
Lanoline 4
Lanonol 4
White oil 5
Mink oil 2
1-positive dodecyl aza cyclohepta-2-ketone 5
Glycerol tristearate 5
Si Ben-60 4
Tween-60 2
Glycerol 5
Hyaluronic acid 0.5
Triumphant loose CG 0.05
Chemical compound 4 15
Chemical compound 2 10
Chemical compound 11 30
Surplus is H
2O complements to 100.
Observation of curative effect on probation:
Urinating, to block the improvement rate be 91%, and it is 67% that the nocturia number of times improves effective percentage, and AFR is increased to (6.7 ± 2.2) ml/s by (4.6 ± 2) ml/s before treating after the treatment.
Embodiment 6
Hexadecanol 5
Lanoline 4
Lanonol 4
White oil 5
Mink oil 2
1-positive dodecyl aza cyclohepta-2-ketone 5
Glycerol tristearate 5
Si Ben-60 4
Tween-60 2
Glycerol 5
Hyaluronic acid 0.5
Triumphant loose CG 0.05
Chemical compound 7 15
Chemical compound 11 15
Chemical compound 10 20
Surplus is H
2O complements to 100.
Observation of curative effect on probation:
Urinating, to block the improvement rate be 89%, and it is 69% that the nocturia number of times improves effective percentage, and AFR is increased to (6.9 ± 2.2) ml/s by (4.7 ± 2) ml/s before treating after the treatment.
Embodiment 7
Hexadecanol 5
Lanoline 4
Lanonol 4
White oil 5
Mink oil 2
1-positive dodecyl aza cyclohepta-2-ketone 5
Glycerol tristearate 5
Si Ben-60 4
Tween-60 2
Glycerol 5
Hyaluronic acid 0.5
Triumphant loose CG 0.05
Chemical compound 7 10
Chemical compound 68
Chemical compound 10 15
Chemical compound 95
Surplus is H
2O complements to 100.
Observation of curative effect on probation:
Urinating, to block the improvement rate be 91%, and it is 67% that the nocturia number of times improves effective percentage, and AFR is increased to (6.8 ± 2.2) ml/s by (4.6 ± 2) ml/s before treating after the treatment.
Embodiment 8
Hexadecanol 5
Lanoline 4
Lanonol 4
White oil 5
Mink oil 2
1-positive dodecyl aza cyclohepta-2-ketone 5
Glycerol tristearate 5
Si Ben-60 4
Tween-60 2
Glycerol 5
Hyaluronic acid 0.5
Triumphant loose CG 0.05
Chemical compound 8 20
Chemical compound 11 5
Surplus is H
2O complements to 100.
Observation of curative effect on probation:
Urinating, to block the improvement rate be 91%, and it is 67% that the nocturia number of times improves effective percentage, and AFR is increased to (6.5 ± 2.2) ml/s by (4.5 ± 2) ml/s before treating after the treatment.
Embodiment 9
Hexadecanol 5
Lanoline 4
Lanonol 4
White oil 5
Mink oil 2
1-positive dodecyl aza cyclohepta-2-ketone 5
Glycerol tristearate 5
Si Ben-60 4
Tween-60 2
Glycerol 5
Hyaluronic acid 0.5
Triumphant loose CG 0.05
Chemical compound 45
Chemical compound 11 8
Chemical compound 12 7
Surplus is H
2O complements to 100.
Observation of curative effect on probation:
Urinating, to block the improvement rate be 92%, and it is 67% that the nocturia number of times improves effective percentage, and AFR is increased to (6.9 ± 2.2) ml/s by (4.5 ± 2) ml/s before treating after the treatment.
Embodiment 10
Hexadecanol 5
Lanoline 4
Lanonol 4
White oil 5
Mink oil 2
1-positive dodecyl aza cyclohepta-2-ketone 5
Glycerol tristearate 5
Si Ben-60 4
Tween-60 2
Glycerol 5
Hyaluronic acid 0.5
Triumphant loose CG 0.05
Chemical compound 1 10
Chemical compound 10 10
Surplus is H
2O complements to 100.
Observation of curative effect on probation:
Urinating, to block the improvement rate be 92%, and it is 67% that the nocturia number of times improves effective percentage, and AFR is increased to (6.6 ± 2.2) ml/s by (4.6 ± 2) ml/s before treating after the treatment.
Raw materials used among the above embodiment all in jin, adjuvant used among the embodiment, all can in daily cosmetics auxiliary agent handbook, find.
Claims (8)
1, the Liniment of treatment benign prostatic hyperplasia (BPH) is characterized in that described Liniment contains any chemical compound of selecting respectively from following A and B two compounds;
Its consumption is counted by weight: category-A 0.1-30, category-B 0.1-50;
The category-A chemical compound is the compound or its salt with structural formula (I), (II):
Wherein R shows the arbitrary group in the following group of generation:
The category-B chemical compound is for having the following compound or its salt of structure formula V, (VI), (VIII):
2, the Liniment of treatment benign prostatic hyperplasia according to claim 1 (BPH) is characterized in that described Liniment contains any two chemical compounds of selecting in any and the category-B chemical compound of selecting respectively from the category-A chemical compound.
3, the Liniment of treatment benign prostatic hyperplasia according to claim 1 (BPH) is characterized in that described Liniment contains any chemical compound of selecting from the category-A chemical compound from any two and the category-B chemical compound selected respectively.
4, the Liniment of treatment benign prostatic hyperplasia according to claim 1 (BPH) is characterized in that described Liniment contains any two chemical compounds of selecting in any two and the category-B chemical compound of selecting respectively from the category-A chemical compound.
5,, it is characterized in that described Liniment consumption counts by weight: category-A 5-25, category-B 5-30 according to the Liniment of the described treatment benign prostatic hyperplasia of above-mentioned arbitrary claim (BPH).
6, the Liniment of treatment benign prostatic hyperplasia according to claim 5 (BPH) is characterized in that described Liniment consumption counts by weight: category-A 10-20, category-B 10-20.
7, the purposes that is used for the treatment of benign prostatic hyperplasia according to the Liniment of above-mentioned arbitrary claim.
8, Liniment according to claim 9 is used for the treatment of the purposes of benign prostatic hyperplasia, it is characterized by Liniment is made cream/frost/Emulsion to be coated on the human body skin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101184767A CN1305477C (en) | 2003-12-18 | 2003-12-18 | Paint for treating benign prostate hyperplasia and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101184767A CN1305477C (en) | 2003-12-18 | 2003-12-18 | Paint for treating benign prostate hyperplasia and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1552330A CN1552330A (en) | 2004-12-08 |
| CN1305477C true CN1305477C (en) | 2007-03-21 |
Family
ID=34338027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101184767A Expired - Lifetime CN1305477C (en) | 2003-12-18 | 2003-12-18 | Paint for treating benign prostate hyperplasia and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1305477C (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1410063A (en) * | 2001-10-09 | 2003-04-16 | 吕汇川 | Embedding agent for long acting blood pressure reducing |
-
2003
- 2003-12-18 CN CNB2003101184767A patent/CN1305477C/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1410063A (en) * | 2001-10-09 | 2003-04-16 | 吕汇川 | Embedding agent for long acting blood pressure reducing |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1552330A (en) | 2004-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1050514C (en) | Antiallergic composition for ophthalmic or nasal use | |
| CN1416806A (en) | Local composition with undifferentiated plant seed cell and ifs usage | |
| CN1791399A (en) | Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators | |
| CN1215338A (en) | Pharmaceutical combination containing a compound having angiotensin II and antagonisti activity | |
| CN1308535A (en) | Farnesyl protein transferase inhibitors for treating arthropathies | |
| CN1791378A (en) | Antifungal nail coat and method of use | |
| CN1160064C (en) | Selective antibiotic composition | |
| CN1080849A (en) | Be used for the treatment of glaucomatous pharmaceutical composition | |
| CN1686267A (en) | Chinese medicinal preparation for channel warming and blood nourishing and its preparation method | |
| CN1225816A (en) | Moisture retaining agent and external-use agent for skin | |
| CN1610828A (en) | Drugs for ameliorating itch, rough skin or hypersensitive skin or for whitening via inhibition of the production and release of stem cell | |
| CN1886128A (en) | Compositions and methods for treating burns | |
| CN1709497A (en) | Miao-medicine composition and its use | |
| CN1367699A (en) | Composition containing extracts of butyrospermum parkii and use as medicament or dietary supplement | |
| CN1476332A (en) | Skin external preparation containing pine pollen or pine pollen extract | |
| CN1305477C (en) | Paint for treating benign prostate hyperplasia and its use | |
| CN1638717A (en) | Cosmetic use of phytosphingosine as slimming agent and cosmetic compositions comprising phytosphingosine | |
| CN1720061A (en) | Compounds that bind P2Y2 or P2Y1 receptors | |
| CN1520300A (en) | Dihydro-triterpenes in treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain | |
| CN1617704A (en) | Composition comprising at least one oxazolin for inhibiting langerhans cell migration, and uses thereof | |
| CN1679807A (en) | Heat-clearing and stranguria-relieving Chinese medicine preparation and production thereof | |
| CN101031310A (en) | Ophthalmic composition containing xanthan gum and amino acid | |
| CN1883645A (en) | Composition for treating acne mainly | |
| CN1042354A (en) | (RS)-and 2-(2,3-dihydro-5-hydroxyl-4,6,7-trimethylbenzene benzofuryl) acetate and 2-2,3-dihydro-5-acetoxyl group-4,6,7-trimethylammonium benzofuryl) acetate and ester thereof, as mucus conditioning agent and anti-hyschaemic medicine and preparation method thereof | |
| CN1208057C (en) | Compound Zedoary Turmeric oil preparation and process for making same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070321 |